AstraZeneca to Buy Amolyt Pharma for up to $1.05 Billion
Britain's AstraZeneca is to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases, more than $1 billion.
rare diseases
Ultragenyx Opens Gene Therapy Manufacturing Plant
US biopharma Ultragenyx Pharmaceutical has opened a gene therapy manufacturing facility in Bedford, Massachusetts, USA. The company said it is one of the first in the US with complete end-to-end gene therapy capabilities, from R&D through to therapeutic production at scale.
Sweden’s Sobi Agrees Merger with CTI BioPharma
Swedish Orphan Biovitrum (Sobi) has agreed a merger with CTI BioPharma, a US biopharmaceutical company focused on blood-related cancers and rare diseases. Through a wholly owned, indirect subsidiary, Sobi plans to commence a cash tender offer that values CTI at $1.7 billion.
Chiesi Closes Amryt Acquisition
Italian biopharma Chiesi has completed its acquisition of Irish rare disease drugmaker Amryt Pharma. The deal, which was originally announced in January, could be worth up to €1.4 billion for Amryt if certain milestones are met for its epidermolysis bullosa (EB) drug Filsuvez.
Amgen Boosts Rare Diseases with Horizon Buy
Amgen has agreed to buy Horizon Therapeutics for $28.3 billion including debt, boosting its portfolio of drugs for rare autoimmune and inflammatory diseases and beating rivals Sanofi and Johnson & Johnson, as well as a fourth unnamed company.
Evotec Enhances Rare Disease Focus with Central Glass Buy
German CDMO Evotec is to acquire compatriot company Central Glass Germany from Japanese owner Central Glass for a nominal price of €1. The transaction, which remains subject to the usual closing conditions, is expected to complete on Nov. 1.
